Table 4:

Outcomes based on risk stratification category

	Low risk, n(%)(MASCC ≥ 21)n=18	High risk, n(%)(MASCC < 21)n=13	p-value
Days of hospitalization, median, range	4 (2–14 days)	6 (3–10 days)	0.123
Positive culture or documented infection	10 (56%)	7 (54%)	0.925
Multiple positive cultures	0 (0%)	1 (8%)	0.419
Positive blood or urine culture	3 (17%)	3 (23%)	0.676
Antibiotic monotherapy at admission	7 (39%)	5 (38%)	0.981
ICU admission	0 (0%)	2 (15%)	0.168
Severe complication	2 (11%)	5 (38%)	0.099
Multiple severe complications (≥2)	1 (6%)	3 (23%)	0.284
Overall mortality	0 (0%)	0 (0%)	-
Death due to neutropenic fever	0 (0%)	0 (0%)	-
ANC on admission, median, range	249 (20, 1309)	150 (0, 990)	0.418
ANC nadir, median, range	249 (0, 1065)	132 (0, 989)	0.464
G-CSF given during hospitalization	9 (50%)	9 (69%)	0.284
Neutropenic ≥7 days	1/17 (6%)	1/13 (8%)	1.000
Chemotherapy delay	6 (33%)	7 (54%)	0.253

⁺⁺Did not reach statistical significant given low sample size, but one may appreciate a clinically distinct difference in outcomes.

^**MASCC: Multinational Association of Supportive Care in Cancer; ICU: intensive care unit; ANC: absolute neutrophil count; G-CSF: granulocyte colony stimulating factor